免疫调定点抑制剂在肝癌肝移植患者中的应用  

Immune checkpoint inhibitors in liver transplantation patients with hepatocellular carcinoma

作　　者：熊俊[1] 万赤丹 Xiong Jun;Wan Chidan(Department of Hepatobiliary Surgery,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,Hubei,China)

机构地区：[1]华中科技大学同济医学院附属协和医院肝胆外科,武汉430022

出　　处：《肝癌电子杂志》2021年第3期30-34,共5页Electronic Journal of Liver Tumor

基　　金：湖北省自然科学基金面上项目(2017CFB634)。

摘　　要：肝癌是恶性程度最高的实体肿瘤之一,肝移植治疗是其目前最有效的治疗方法。但是绝大部分患者初诊时已超出了肝移植标准,同时术后肿瘤复发也严重影响患者长期生存。目前免疫治疗是实体肿瘤治疗的新方向,可能使肝癌患者肿瘤得到良好的控制,以实现对肿瘤的降期或对复发肿瘤的清除。在本篇综述中,我们主要讨论免疫调定点抑制剂在肝移植前降期或桥接治疗,以及肝移植后肿瘤复发治疗中应用的现状以及目前研究的进展。Hepatocellular carcinoma(HCC)is one of the most malignant solid tumors.Liver transplantation is currently the most effective treatment for HCC.However,most of the patients have exceeded the transplantation standards when they are first diagnosed.Besides,the recurrence of tumors after surgery also seriously affects the long-term survival of patients who have accepted transplantation.Immunotherapy is a new treatment of solid tumors.Some HCC patients who received immunotherapy achieved tumor downgrading or elimination in previous reports.In this review,we mainly discuss current research progress of immune checkpoint inhibitors in the downstage or bridging therapy before liver transplantation,as well as in the treatment of recurrence cancer after liver transplantation.

关 键 词：肝癌 肝移植 免疫治疗 

分 类 号：R735.7[医药卫生—肿瘤]